Up 48% in 5 Days, This Stock is Soaring (and Headed Higher?)

Hims & Hers (HIMS) is soaring. Shares are up about 48% in the past week and could be headed even higher. Here’s what’s going on…

The Catalysts Behind the Breakout

Hims & Hers is a consumer health and telehealth platform. In plain English, it sells online subscriptions for treatments tied to areas like weight loss, sexual health, mental health, dermatology, and other recurring health needs — making it a direct play on the fast-growing shift toward digital, personalized healthcare.

The big spark here was FDA-related peptide news. That’s when the story really caught fire.

In short, U.S. health officials, including HHS Secretary RFK Jr., signaled a more flexible stance toward peptide therapies and kicked off a formal review process that could help pull parts of the peptide market out of the gray area and into something more mainstream.

Why did that matter for Hims? Because the company already owns a U.S.-based peptide manufacturing facility in California. So if the rules start getting clearer and the market opens up, Hims may already have the factory built while others are still drawing up the blueprints.

That kind of regulatory shift can change the way investors value a business in a hurry. Instead of seeing Hims as a company skating around the edges of a controversial market, investors can start imagining a path where it becomes one of the better-positioned players in a category that suddenly looks a lot more legitimate.

And that fresh catalyst landed on top of a story that had already been getting stronger. Back on March 9, Hims announced a strategic “peace treaty” with Novo Nordisk, moving away from a shakier copycat-style model and toward a cleaner branded-drug relationship.

That Novo shift matters because it changes how the whole story feels. Instead of leaning so heavily on a controversial workaround, Hims is moving toward something that looks safer legally, more credible to investors, and easier for customers to trust.

The company is also expanding internationally. Its planned $1.15 billion acquisition of Eucalyptus would bring in more than 775,000 subscribers and strengthen Hims’ position in premium weight-loss brands like Juniper. That gives the company a much broader platform story than just a U.S. telehealth app.

And this isn’t just hype. Hims recently reported more than 2.5 million subscribers, with 2025 revenue rising about 59% year over year to roughly $2.35 billion, alongside positive net income and strong adjusted EBITDA. Management’s 2026 outlook also points to another step up in both revenue and profitability.

There’s also a technology angle here. Hims has been pushing deeper into AI-driven personalization, which the company believes can improve customer retention, increase subscription stickiness, and make the platform more valuable over time.

How the Move Has Built

HIMS didn’t jump all at once. The stock started moving earlier in the week, but the rally clearly accelerated on April 16 once the FDA / peptide story came into focus.

If needed, swipe or scroll sideways to view the full table.

That adds up to a gain of about 48.3%, from $19.43 on April 10 to $28.82 on April 17. In other words, this wasn’t a one-day pop — it was a full-week momentum run that accelerated once the peptide-regulation story came into focus.

Put it all together, and HIMS looks like more than just a short squeeze or random momentum burst. The stock has been climbing on a mix of regulatory tailwinds, a cleaner weight-loss story, and improving sentiment around future growth.

Of course, this is not a risk-free story. Competition remains real — especially with Amazon pushing further into prescription delivery and GLP-1 convenience. And investors will also be watching whether Hims can actually protect margins as the branded-drug model evolves.

Still, right now the combination of a more credible GLP-1 strategy, possible peptide regulatory tailwinds, international expansion, and a bullish technical breakout makes HIMS one of the more interesting setups on the board.

Unusual Options Activity

One more thing worth noting: the options market was getting unusually bullish before the FDA-related peptide news hit. On April 15, a cluster of 20+ aggressive call buying showed up across multiple strikes and expirations — before the FDA news dropped on April 16. Here are three of the biggest trades:

If needed, swipe or scroll sideways to view the full table.

This doesn’t prove anything by itself, of course. But it does suggest traders were leaning bullish on HIMS before the headline catalyst became public — exactly the kind of signal worth noting when momentum starts building.

These unusual option trades and big headlines may have helped light the fire, but the chart is what could determine whether this move has real staying power. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Downtrend Channel Breakout: Over the past few weeks, the stock had been trapped inside a downtrend channel, marked by the purple lines on the daily chart. Now it has broken out above that range — and that’s often the kind of move that can signal a real shift in character. Once a stock pushes through the upper rail of a downtrend channel, it can open the door to a stronger move higher.

#2 Price above MA: The stock is also trading above its 50-day moving average, which is another sign that the bulls still have control of the near-term trend. That’s exactly where you want to see it if momentum is starting to build.

#3 MACD Above Signal Line: Momentum is leaning bullish too. On the daily chart, the MACD line (light blue color) is sitting above the signal line (orange color), which is usually a sign that upside momentum is starting to build rather than fade.

#4 Bullish ADX: The trend-strength picture looks constructive as well. The +DI line remains above the –DI line, and the ADX line has pushed above the –DI line too — a sign that bullish momentum may be starting to gain some traction.

#5 Above Support Area: The weekly chart is telling a bullish story too. The stock has pushed higher from a former resistance level that now looks like support, marked by the pink dotted line. That kind of flip is exactly what bulls want to see, because it suggests the stock may be building a solid base for another move higher. Add in the fact that shares are still trading above the 200-week moving average, and the bigger-picture trend still looks supportive.

#6 %K above %D: Momentum may be starting to turn higher on the weekly chart as well. The %K line (blue) of the stochastic indicator has crossed above the %D line (orange), which is often an early sign that the bulls are starting to regain control.

#7 Positive OBV: Volume is leaning in the bulls’ favor too. The weekly OBV line is rising, which tells us buying pressure has been stronger on the up weeks than selling pressure on the down weeks. That’s often the kind of volume behavior you want to see when a stock is trying to push higher.

Recommended Trade Setup

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $6.00 per share, the target rewards are about $10.80 and $18.80 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Risks to Consider

Even strong setups can fail, especially after a move this sharp. A few things could knock HIMS off course:

• A breakdown back below the trend channel on heavy volume
• Negative company-specific news or broader market weakness that pressures high-growth healthcare names
• Fresh regulatory changes that hurt sentiment around peptides, GLP-1s, or the broader telehealth / compounding space
• Amazon Pharmacy’s launch of Foundayo, Lilly’s GLP-1 offering with same-day delivery, which directly challenges one of Hims’ biggest selling points: convenience
• Heavy insider selling, with both the CEO and CFO unloading several million dollars’ worth of shares over the last quarter — something that may make investors a little more cautious
• A 48% run in just 5 trading days is the kind of move that can easily lead to a near-term pause, pullback, or consolidation even if the bigger story remains intact

Happy Trading!
Tara and Greg